Be part of the knowledge.™

Project Oncology®

Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.

Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.

245

LikeLikedUnlike

61-75 of 360

Examining Unmet Needs in Paroxysmal Nocturnal Hemoglobinuria
Project Oncology®
Examining Unmet Needs in Paroxysmal Nocturnal Hemoglobinuria
- Brian P. McDonough, MD, FAAFP
  Peer
Conquering the Burden & Impacts of PNH
Project Oncology®
Conquering the Burden & Impacts of PNH
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Hana Safah, MD
  Peer
- Timothy Kubal, MD
  Peer
Improving PNH Patient Outcomes
Project Oncology®
Improving PNH Patient Outcomes
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- David Dingli, MD, PhD
  Peer
Examining the Treatment Paradigm for Paroxysmal Nocturnal Hemoglobinuria
Project Oncology®
Examining the Treatment Paradigm for Paroxysmal Nocturnal Hemoglobinuria
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Brian Mulherin, MD
  Peer
Managing PNH Patients: Addressing the Unmet Needs
Project Oncology®
Managing PNH Patients: Addressing the Unmet Needs
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Brian Mulherin, MD
  Peer
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Project Oncology®
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
advertisement
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
- Ryan Quigley
  Peer
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Project Oncology®
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Project Oncology®
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Project Oncology®
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Real-World CDK4/6 Inhibitor Patterns in HR+/HER2– Metastatic Breast Cancer
Project Oncology®
Real-World CDK4/6 Inhibitor Patterns in HR+/HER2– Metastatic Breast Cancer
- Pavani Chalasani, MD, MPH
  Peer
- Adam Brufsky, MD, PhD
  Peer
Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
Project Oncology®
Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
- Jennifer Caudle, DO, FACOFP
  Peer
- Samuel Klempner, MD
  Peer
- Nataliya Uboha, MD, PhD
  Peer
advertisement
Assessing Atirmociclib Plus Letrozole in HR+/HER2- Metastatic Breast Cancer
Project Oncology®
Assessing Atirmociclib Plus Letrozole in HR+/HER2- Metastatic Breast Cancer
- Pavani Chalasani, MD, MPH
  Peer
- Antonio Giordano, MD, PhD
  Peer
Axatilimab for cGVHD: Assessing Organ-Specific Responses in AGAVE-201
Project Oncology®
Axatilimab for cGVHD: Assessing Organ-Specific Responses in AGAVE-201
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Shernan Holtan, MD
  Peer
- Alicia Lieberman, MD, MS
  Peer
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Project Oncology®
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Luhua (Michael) Wang, MD
  Peer

Program Chapters

Segment Chapters

Playlist:

Recommended